Drug Trial Radar · NCT06532578
Evaluate the Safety and Efficacy of CPX101 in Overweight and Obese Subjects Without Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
240
Actual
Start
Aug 13, 2024
Primary completion
Dec 15, 2025
Study completion Apr 1, 2026
Sponsor
- Lead sponsor
- Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is designed to evaluate the preliminary efficacy, safety, population PK profile, and immunogenicity of CPX101 in subjects with obesity or overweight with weight related comorbidities but without diabetes mellitus.
Conditions
- Overweight and Obesity
Interventions
CPX101 or placebo 120mg Q2WBiological
Subcutaneous injection of CPX101 or placebo
CPX101 or placebo 160mg Q4WBiological
Subcutaneous injection of CPX101 or placebo
CPX101 or placebo 160mg Q2WBiological
Subcutaneous injection of CPX101 or placebo
CPX101 or placebo 240mg Q4WBiological
Subcutaneous injection of CPX101 or placebo
CPX101 or placebo 240mg Q2WBiological
Subcutaneous injection of CPX101 or placebo
CPX101 or placebo 320mg Q2WBiological
CPX101 or placebo 320mg Q2W
CPX101 or placebo 360mg Q4WBiological
CPX101 or placebo 360mg Q4W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of CPX101 in body weight loss in KgTime frame: Up to 24 weeks after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Paratus Clinical Research
Chatswood, New South Wales, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.